Drug for stimulating glucagon-like peptide 1 (GLP-1) secretion

A glucagon and drug technology, applied in the field of diabetes prevention and treatment, can solve the problems of degradation, test results affected by various factors, and limitations of GLP-1 clinical application, so as to achieve the effect of preventing and controlling diabetes and promoting secretion

Inactive Publication Date: 2012-09-19
惠宏襄
View PDF2 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the clinical application of GLP-1 also faces a problem, that is, the GLP-1 produced by the human body is easily degraded by dipeptidyl peptidase IV (DPP-IV) in the body, and its plasma half-life is less than 2 minutes. Continuous intravenous infusion or continuous subcutaneous injection can produce curative effect, which greatly limits the clinical application of GLP-1
[0007] Some traditional Chinese medicine can lower blood sugar, but its test results are affected by many factors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0018] The present invention will be described in detail below. It should be noted that the following examples are used to illustrate the present invention rather than limit the present invention. Although the present invention has been described in detail with preferred embodiments, those of ordinary skill in the art should understand that the present invention can be modified, deformed or equivalently replaced without departing from the scope of the present invention, all of which belong to the protection of the present invention scope.

[0019] 1. Probiotic culture:

[0020] Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium adolescent, Bifidobacterium infantis and Bifidobacterium bifidum. The strains were provided by Anderson Biotechnology Company (1008 Ashbourne Place, Los Angeles, California, USA).

[0021] 20% PTYG medium. PTYG contains: tryptone 5 g, yeast extract 10 g, soybean peptone 5 g, glucose 10 g, Tween-80 1 mL, saline solution 40 mL, 0.1% resazur...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a drug for stimulating diabetes-related glucagon-like peptide 1 (GLP-1) secretion, falling into the field of diabetes prevention and treatment. The drug for stimulating GLP-1 secretion comprises effective dosage of probiotic bacteria, and effective dosage of Rhizoma Coptidis extract. The drug can effectively stimulate cell to secrete GLP-1 and improve quality of intestinal flora especially probiotic bacteria, and combines with Chinese medicinal ingredients to promote GLP-1 secretion, thereby preventing and treating diabetes.

Description

technical field [0001] The invention belongs to the field of prevention and treatment of diabetes, in particular to a drug for stimulating the secretion of glucagon-like peptide-1 related to diabetes. Background technique [0002] Diabetes is a disease in which blood sugar levels are higher than normal. There are three main types of diabetes, namely type 1 diabetes (juvenile diabetes), type 2 diabetes and gestational diabetes. In type 1 diabetes, the beta cells of the pancreas do not make enough insulin. Type 2 diabetes is the main form of diabetes, accounting for about 90-95% of all diabetic patients. This type of diabetes usually begins with insulin resistance, a condition in which muscle, liver and fat cells do not respond properly to insulin. The pancreas eventually loses its ability to produce and secrete enough insulin in response to food intake. Gestational diabetes is caused by hormonal changes during pregnancy or by insufficient insulin. Glucose in the blood ca...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/74A61K36/718A61P3/10A61K31/4375A61K35/745
Inventor 惠宏襄赵小宁孙伟成王剑英
Owner 惠宏襄
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap